Eli Lilly and Company

Activity from announced rounds

Activity in this selectionolive-tree-capital-afa6a86e
Rounds participated in
16
Confirmed lead rounds
0
10 roles undisclosed
New companies
16
First participation on record · 0 follow-on
Funding in participating rounds
$1.2B
16 disclosed · full round size, not this investor’s share

By stage

Series B7
Series C+3
Seed2
Series A2
Undisclosed2

By primary sector

Biotech14
Healthtech2

By country

United States14
Australia1
United Kingdom1

Rounds

16 in this selection
General Medicine

An online healthcare store where people compare care options and upfront prices, book visits and order medications or lab tests.

$120MSeries B
Participant
Thatch

A health-benefits platform that lets employers set healthcare budgets while employees choose insurance and eligible care to fit their needs.

$108MNew funding
Participant
Circle Pharma, Inc.

Circle Pharma discovers macrocycle medicines for cancer and other serious diseases using its MXMO platform, which combines computational, structure-based design with synthetic chemistry to create cell-permeable compounds against difficult protein targets. Its lead programs are investigational and at discovery or preclinical stages.

$92.5MSeries E
Participant
Moonwalk Biosciences

Moonwalk Biosciences is developing adipose-targeted siRNA medicines for obesity and cardiometabolic disease. Its lead programs are designed to alter fat-tissue pathways while limiting effects on other tissues, with the lead obesity candidate in IND-enabling development ahead of planned human testing in 2027.

$70MSeries B
Participant
Cloverleaf Bio

Cloverleaf Bio is developing engineered transfer RNA therapies that use a modified tRNA payload to inhibit cancer cells' RNA-modifying enzymes. Its lead program targets liver cancer and is advancing toward clinical testing; a second antibody-tRNA program for colorectal cancer remains preclinical.

$33MSeed
Participant
Superluminal Medicines

Superluminal Medicines combines structural biology, protein dynamics, machine learning and experimental testing to discover small-molecule drugs for difficult G protein-coupled receptor targets. Its pipeline focuses on endocrine and cardiometabolic diseases, including rare genetic and hypothalamic obesity.

$60MSeries B
Participant
Leal Therapeutics

Develops neuro-metabolic therapeutics for schizophrenia and ALS

$30MSeries A
Role not disclosed
InduPro

Develops proximity-guided antibody-drug conjugate therapeutics for cancer and autoimmune disease

$77MSeries B
Role not disclosed
Remedium Bio

Develops durable protein therapeutics via gene therapy for chronic diseases

$10MSeries A
Role not disclosed
Ratio Therapeutics

Developing best-in-class radiopharmaceuticals for cancer treatment

$70MSeries C
Role not disclosed
AdvanCell

Develops lead-212 targeted alpha therapies to treat cancer

$315MSeries D
Role not disclosed
TRIMTECH Therapeutics

Develops small molecule therapies to degrade protein aggregates in neurodegenerative diseases

$47MSeed+
Role not disclosed
Crossbow Therapeutics

Develops a novel class of potent and precise antibody therapies to treat a broad range of cancers

$77MSeries B
Role not disclosed
TRex Bio

Develops precision immunoregulatory medicines based on tissue Treg biology

$50MUndisclosed
Role not disclosed